|
1
|
Erickson LA, Rivera M and Zhang J:
Adrenocortical carcinoma: Review and update. Adv Anat Pathol.
21:151–159. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Stigliano A, Cerquetti L, Lardo P,
Petrangeli E and Toscano V: New insights and future perspectives in
the therapeutic strategy of adrenocortical carcinoma (Review).
Oncol Rep. 37:1301–1311. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wang HW, Wu YH, Hsieh JY, Liang ML, Chao
ME, Liu DJ, Hsu MT and Wong TT: Pediatric primary central nervous
system germ cell tumors of different prognosis groups show
characteristic miRNome traits and chromosome copy number
variations. BMC Genomics. 11(132)2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Soon PS, Gill AJ, Benn DE, Clarkson A,
Robinson BG, McDonald KL and Sidhu SB: Microarray gene expression
and immunohistochemistry analyses of adrenocortical tumors identify
IGF2 and Ki-67 as useful in differentiating carcinomas from
adenomas. Endocr Relat Cancer. 16:573–583. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Szabó PM, Wiener Z, Tömböl Z, Kovács A,
Pócza P, Horányi J, Kulka J, Riesz P, Tóth M, Patócs A, et al:
Differences in the expression of histamine-related genes and
proteins in normal human adrenal cortex and adrenocortical tumors.
Virchows Arch. 455:133–142. 2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gene Ontology Consortium. Gene ontology
consortium: Going forward. Nucleic Acids Res. 43 (Database
Issue):D1049–D1056. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kanehisa M, Goto S, Furumichi M, Tanabe M
and Hirakawa M: KEGG for representation and analysis of molecular
networks involving diseases and drugs. Nucleic Acids Res. 38
(Database Issue):D355–D360. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Huang DW, Sherman BT, Tan Q, Collins JR,
Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC and Lempicki
RA: The DAVID gene functional classification tool: A novel
biological module-centric algorithm to functionally analyze large
gene lists. Genome Biol. 8(R183)2007.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Franceschini A, Szklarczyk D, Frankild S,
Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C
and Jensen LJ: STRING v9.1: Protein-protein interaction networks,
with increased coverage and integration. Nucleic Acids Res. 41
(Database Issue):D808–D815. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Rivera CG, Vakil R and Bader JS: NeMo:
Network module identification in cytoscape. BMC Bioinformatics.
11(S61)2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Maere S, Heymans K and Kuiper M: BiNGO: A
Cytoscape plugin to assess overrepresentation of gene ontology
categories in biological networks. Bioinformatics. 21:3448–3449.
2005.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Goldman M, Craft B, Swatloski T, Ellrott
K, Cline M, Diekhans M, Ma S, Wilks C, Stuart J, Haussler D and Zhu
J: The UCSC cancer genomics browser: Update 2013. Nucleic Acids
Res. 41 (Database Issue):D949–D954. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Giordano TJ, Thomas DG, Kuick R, Lizyness
M, Misek DE, Smith AL, Sanders D, Aljundi RT, Gauger PG, Thompson
NW, et al: Distinct transcriptional profiles of adrenocortical
tumors uncovered by DNA microarray analysis. Am J Pathol.
162:521–531. 2003.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Giordano TJ, Kuick R, Else T, Gauger PG,
Vinco M, Bauersfeld J, Sanders D, Thomas DG, Doherty G and Hammer
G: Molecular classification and prognostication of adrenocortical
tumors by transcriptome profiling. Clin Cancer Res. 15:668–676.
2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Else T, Kim AC, Sabolch A, Raymond VM,
Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ and Hammer
GD: Adrenocortical carcinoma. Endocr Rev. 35:282–326.
2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Harjunpää H, Llort Asens M, Guenther C and
Fagerholm SC: Cell adhesion molecules and their roles and
regulation in the immune and tumor microenvironment. Front Immunol.
10(1078)2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Revilla G, Corcoy R, Moral A, Escolà-Gil
JC and Mato E: Cross-talk between inflammatory mediators and the
epithelial mesenchymal transition process in the development of
thyroid carcinoma. Int J Mol Sci. 20: pii(E2466)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Antunes DM, Rodrigues MFSD, Guimarães DM,
Duarte CME, Miguita L, Corrêa L, DE Oliveira APL, Fernandes KPS and
Nunes FD: Nonsteroidal anti-inflammatory drugs modulate gene
expression of inflammatory mediators in oral squamous cell
carcinoma. Anticancer Res. 39:2385–2394. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Qu X, Tang Y and Hua S: Immunological
approaches towards cancer and inflammation: A cross talk. Front
Immunol. 9(563)2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Macciò A and Madeddu C: Blocking
inflammation to improve immunotherapy of advanced cancer.
Immunology. 159:357–364. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Xiao H, Xu D, Chen P, Zeng G, Wang X and
Zhang X: Identification of five genes as a potential biomarker for
predicting progress and prognosis in adrenocortical carcinoma. J
Cancer. 9:4484–4495. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yamane T, Asanoma K, Kobayashi H, Liu G,
Yagi H, Ohgami T, Ichinoe A, Sonoda K, Wake N and Kato K:
Identification of the critical site of calponin 1 for suppression
of ovarian cancer properties. Anticancer Res. 35:5993–5999.
2015.PubMed/NCBI
|
|
24
|
Yanagisawa Y, Takeoka M, Ehara T, Itano N,
Miyagawa S and Taniguchi S: Reduction of Calponin h1 expression in
human colon cancer blood vessels. Eur J Surg Oncol. 34:531–537.
2008.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Liu Y, Wu X, Wang G, Hu S, Zhang Y and
Zhao S: CALD1, CNN1, and TAGLN identified as potential prognostic
molecular markers of bladder cancer by bioinformatics analysis.
Medicine (Baltimore). 98(e13847)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhou CZ, Qiu GQ, Wang XL, Fan JW, Tang HM,
Sun YH, Wang Q, Huang F, Yan DW, Li DW and Peng ZH: Screening of
tumor suppressor genes on 1q31.1-32.1 in Chinese patients with
sporadic colorectal cancer. Chin Med J (Engl). 121:2479–2486.
2008.PubMed/NCBI
|
|
27
|
Hirasawa Y, Arai M, Imazeki F, Tada M,
Mikata R, Fukai K, Miyazaki M, Ochiai T, Saisho H and Yokosuka O:
Methylation status of genes upregulated by demethylating agent
5-aza-2'-deoxycytidine in hepatocellular carcinoma. Oncology.
71:77–85. 2006.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Jin GH, Xu W, Shi Y and Wang LB: Celecoxib
exhibits an anti-gastric cancer effect by targeting focal adhesion
and leukocyte transendothelial migration-associated genes. Oncol
Lett. 12:2345–2350. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Davalieva K, Kostovska IM, Kiprijanovska
S, Markoska K, Kubelka-Sabit K, Filipovski V, Stavridis S, Stankov
O, Komina S, Petrusevska G and Polenakovic M: Proteomics analysis
of malignant and benign prostate tissue by 2D DIGE/MS reveals new
insights into proteins involved in prostate cancer. Prostate.
75:1586–1600. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Yang J, Song H, Chen L, Cao K, Zhang Y, Li
Y and Hao X: Integrated analysis of microfibrillar-associated
proteins reveals MFAP4 as a novel biomarker in human cancers.
Epigenomics. 11:1635–1651. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhao H, Sun Q, Li L, Zhou J, Zhang C, Hu
T, Zhou X, Zhang L, Wang B, Li B, et al: High expression levels of
AGGF1 and MFAP4 predict primary platinum-based chemoresistance and
are associated with adverse prognosis in patients with serous
ovarian cancer. J Cancer. 10:397–407. 2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Niu D, Peatman E, Liu H, Lu J, Kucuktas H,
Liu S, Sun F, Zhang H, Feng T, Zhou Z, et al:
Microfibrillar-associated protein 4 (MFAP4) genes in catfish play a
novel role in innate immune responses. Dev Comp Immunol.
35:568–579. 2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Schlosser A, Pilecki B, Hemstra LE,
Kejling K, Kristmannsdottir GB, Wulf-Johansson H, Moeller JB,
Füchtbauer EM, Nielsen O, Kirketerp-Møller K, et al: MFAP4 promotes
vascular smooth muscle migration, proliferation and accelerates
neointima formation. Arterioscler Thromb Vasc Biol. 36:122–133.
2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Schluterman MK, Chapman SL, Korpanty G,
Ozumi K, Fukai T, Yanagisawa H and Brekken RA: Loss of fibulin-5
binding to beta1 integrins inhibits tumor growth by increasing the
level of ROS. Dis Model Mech. 3:333–342. 2010.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Dou CY, Cao CJ, Wang Z, Zhang RH, Huang
LL, Lian JY, Xie WL and Wang LT: EFEMP1 inhibits migration of
hepatocellular carcinoma by regulating MMP2 and MMP9 via ERK1/2
activity. Oncol Rep. 35:3489–3495. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Topalovski M, Hagopian M, Wang M and
Brekken RA: Hypoxia and transforming growth factor β cooperate to
induce fibulin-5 expression in pancreatic cancer. J Biol Chem.
291:22244–22252. 2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Pannu H, Tran-Fadulu V, Papke CL, Scherer
S, Liu Y, Presley C, Guo D, Estrera AL, Safi HJ, Brasier AR, et al:
MYH11 mutations result in a distinct vascular pathology driven by
insulin-like growth factor 1 and angiotensin II. Hum Mol Genet.
16:2453–2462. 2007.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Assaf N, El-Cheikh J, Bazarbachi A, Salem
Z, Farra C, Chakhachiro Z, Nassif S, Zaatari G and Mahfouz R:
Molecular profiling of adult acute myeloid and lymphoid leukemia in
a major referral center in Lebanon: A 10-year experience report and
review of the literature. Mol Biol Rep. 46:2003–2011.
2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Friedl P and Wolf K: Tumour-cell invasion
and migration: Diversity and escape mechanisms. Nat Rev Cancer.
3:362–374. 2003.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Lee WS, Seo G, Shin HJ, Yun SH, Yun H,
Choi N, Lee J, Son D, Cho J, Kim J, et al: Identification of
differentially expressed genes in microsatellite stable HNPCC and
sporadic colon cancer. J Surg Res. 144:29–35. 2008.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Alhopuro P, Karhu A, Winqvist R, Waltering
K, Visakorpi T and Aaltonen LA: Somatic mutation analysis of MYH11
in breast and prostate cancer. BMC Cancer. 8(263)2008.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Song L, Li XX, Liu XY, Wang Z, Yu Y, Shi
M, Jiang B and He XP: EFEMP2 suppresses the invasion of lung cancer
cells by inhibiting epithelial-mesenchymal transition (EMT) and
down-regulating MMPs. Onco Targets Ther. 13:1375–1396.
2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Zhou Q, Chen S, Lu M, Luo Y, Wang G, Xiao
Y, Ju L and Wang X: EFEMP2 suppresses epithelial-mesenchymal
transition via Wnt/β-catenin signaling pathway in human bladder
cancer. Int J Biol Sci. 15:2139–2155. 2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Khapchaev AY and Shirinsky VP: Myosin
light Chain kinase MYLK1: Anatomy, interactions, functions, and
regulation. Biochemistry (Mosc). 81:1676–1697. 2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Kim DY and Helfman DM: Loss of MLCK leads
to disruption of cell-cell adhesion and invasive behavior of breast
epithelial cells via increased expression of EGFR and ERK/JNK
signaling. Oncogene. 35:4495–4508. 2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Dai Y, Li D, Chen X, Tan X, Gu J, Chen M
and Zhang X: Circular RNA myosin light chain kinase (MYLK) promotes
prostate cancer progression through modulating Mir-29a expression.
Med Sci Monit. 24:3462–3471. 2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Zhong Z, Huang M, Lv M, He Y, Duan C,
Zhang L and Chen J: Circular RNA MYLK as a competing endogenous RNA
promotes bladder cancer progression through modulating VEGFA/VEGFR2
signaling pathway. Cancer Lett. 403:305–317. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Nakamura Y, Yamazaki Y, Felizola SJ, Ise
K, Morimoto R, Satoh F, Arai Y and Sasano H: Adrenocortical
carcinoma: Review of the pathologic features, production of adrenal
steroids, and molecular pathogenesis. Endocrinol Metab Clin North
Am. 44:399–410. 2015.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Lowery AJ, Walsh S, McDermott EW and
Prichard RS: Molecular and therapeutic advances in the diagnosis
and management of malignant pheochromocytomas and paragangliomas.
Oncologist. 18:391–407. 2013.PubMed/NCBI View Article : Google Scholar
|
|
50
|
de Wailly P, Oragano L, Radé F, Beaulieu
A, Arnault V, Levillain P and Kraimps JL: Malignant
pheochromocytoma: New malignancy criteria. Langenbecks Arch Surg.
397:239–246. 2012.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Aporowicz M, Czopnik P, Kubicka E,
Piotrowska A, Dziegiel P, Bolanowski M and Domoslawski P:
Minichromosome maintenance proteins MCM-3, MCM-5, MCM-7, and Ki-67
as proliferative markers in adrenocortical tumors. Anticancer Res.
39:1151–1159. 2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Saiegh L, Sheikh-Ahmad M, Shechner C, Reut
M, Darawsha Y, Zolotov S, Shefer H, Bejar I and Bejar J:
Metallothionein protein and minichromosome maintenance protein-2
expression in adrenocortical tumors. Ann Endocrinol (Paris).
80:324–328. 2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Romero Arenas MA, Whitsett TG, Aronova A,
Henderson SA, LoBello J, Habra MA, Grubbs EG, Lee JE, Sircar K,
Zarnegar R, et al: Protein expression of PTTG1 as a diagnostic
biomarker in adrenocortical carcinoma. Ann Surg Oncol. 25:801–807.
2018.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Hirano Y, Nobata S, Takahashi H, Kageyama
S, Sudoko H, Ushiyama T, Suzuki K and Fujita K: Histologically
benign but telomerase positive adrenal pheochromocytoma. Int J
Urol. 9:697–699. 2002.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Kołomecki K, Stepień H and Narebski JM:
Vascular endothelial growth factor and basic fibroblast growth
factor evaluation in blood serum of patients with hormonally active
and inactive adrenal gland tumours. Cytobios. 101:55–64.
2000.PubMed/NCBI
|
|
56
|
Li L, Lei Q, Zhang S, Kong L and Qin B:
Screening and identification of key biomarkers in hepatocellular
carcinoma: Evidence from bioinformatic analysis. Oncol Rep.
38:2607–2618. 2017.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Panvichian R, Tantiwetrueangdet A,
Angkathunyakul N and Leelaudomlipi S: TOP2A amplification and
overexpression in hepatocellular carcinoma tissues. Biomed Res Int.
2015(381602)2015.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Wong N, Yeo W, Wong WL, Wong NL, Chan KY,
Mo FK, Koh J, Chan SL, Chan AT, Lai PB, et al: TOP2A overexpression
in hepatocellular carcinoma correlates with early age onset,
shorter patients survival and chemoresistance. Int J Cancer.
124:644–652. 2009.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Guo J, Gu Y, Ma X, Zhang L, Li H, Yan Z,
Han Y, Xie L and Guo X: Identification of hub genes and pathways in
adrenocortical carcinoma by integrated bioinformatic analysis. J
Cell Mol Med. 24:4428–4438. 2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Button KS, Ioannidis JP, Mokrysz C, Nosek
BA, Flint J, Robinson ES and Munafò MR: Power failure: Why small
sample size undermines the reliability of neuroscience. Nat Rev
Neurosci. 14:365–376. 2013.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Celestino R, Nome T, Pestana A, Hoff AM,
Gonçalves AP, Pereira L, Cavadas B, Eloy C, Bjøro T,
Sobrinho-Simões M, et al: CRABP1, C1QL1 and LCN2 are biomarkers of
differentiated thyroid carcinoma, and predict extrathyroidal
extension. BMC Cancer. 18(68)2018.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Pinato DJ, Black JR, Trousil S, Dina RE,
Trivedi P, Mauri FA and Sharma R: Programmed cell death ligands
expression in phaeochromocytomas and paragangliomas: Relationship
with the hypoxic response, immune evasion and malignant behavior.
Oncoimmunology. 6(e1358332)2017.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Zhang L, Luo B, Dang YW, He RQ, Peng ZG,
Chen G and Feng ZB: Clinical significance of microRNA-196b-5p in
hepatocellular carcinoma and its potential molecular mechanism. J
Cancer. 10:5355–5370. 2019.PubMed/NCBI View Article : Google Scholar
|
